SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The $ROSIE project centers around a unique, AI-powered memecoin inspired by "Rosie the Robot," a beloved character known for her role as a caring, motherly robot in popular culture. The purpose of $ROSIE is twofold: entertainment through an interactive AI feature and social impact via charitable donations.  Users can interact with an AI version of Rosie on the project’s website, where they can ask questions and engage in conversations. The utility of $ROSIE goes beyond typical memecoins by enabling users to donate tokens, which will be directed towards charitable causes supporting mothers. Through this initiative, the project combines the viral appeal of meme tokens with meaningful contributions to social causes, while leveraging AI technology to create a novel user experience.

Rosie the Robot

ROSIE CRYPTO is gaining attention, particularly regarding its integration with Phantom Wallet. The community highlights the token's 'early moon' potential and strong momentum, suggesting a possible breakout. Bullish sentiment is building, with many emphasizing it as an opportune entry point.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending due to an FDA investigation into allergic reactions linked to specific lots of its and Grifols' immune globulin products, raising concerns about potential voluntary recalls and revenue impact. The community is discussing the extent of the issue, comparing it to a previous recall, and speculating on possible short-selling manipulation. Despite the concerns, some investors express confidence in the company's fundamentals and long-term growth potential, viewing the dip as a buying opportunity.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending due to renewed interest in its low float and potential for a short squeeze, with some traders drawing comparisons to other high-flying stocks. Community chatter highlights the company's potential crypto treasury and anticipation for news catalysts. Some are wary of the stock's history of volatility and advising caution.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto community discusses its recent price movements and potential catalysts, including the ongoing government shutdown and anticipation of XRP ETFs.  Community members are debating entry points, long-term potential, and whether XRP can break through resistance levels.  Broader discussions include Ripple's partnerships and the potential impact of regulatory clarity on the crypto's future.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals ($SNDX) is trending due to an upcoming FDA decision on their drug Revuforj for a specific type of leukemia, with the community debating the likelihood of approval and its potential impact. Some traders point to the drug's existing approval for a related condition and analysts' price targets while others cite concerns about side effects and market manipulation. Discussions also mention potential competition and buyout scenarios.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending due to recent listing news and a surge in interest surrounding its AI agent ecosystem. Community members are actively discussing its potential, the utility of its agents, and possible price targets. The broader context includes the growing excitement around AI-related crypto projects and Base network tokens.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

Picard Medical (PMI) is trending due to recent stock volatility, leading the company to release a statement clarifying they are unaware of any undisclosed material changes. The community is actively discussing potential Monday catalysts, dilution concerns, and whether the stock presents a buying opportunity or a trap. Bullish sentiment revolves around the company's exclusive artificial heart technology and potential for a v-shape recovery.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is trending as its community rallies around the project, anticipating a significant breakout. The community, known as the Wolfpack, expresses strong conviction and emphasizes holding for long-term gains. Discussions highlight the project's potential and a belief that a substantial upward movement is on the horizon.

PAW Chain has launched the world’s first Layer 3-centric blockchain, enhancing scalability and inter-chain operability across networks. The roadmap features a decentralized exchange, merchant services, and a DAO, all optimized for high-volume, low-cost transactions. Leveraging smart contracts and EVM compatibility, PAW Chain is set to transform digital finance by providing secure, efficient solutions, allowing any project to go multi-chain, underscored by a community-driven governance model and rigorous security standards including regular security audits.

$PAW is trending amidst community excitement surrounding its multi-chain ecosystem and ongoing development, including news about new projects launching and validator updates. Community members express bullish sentiment, focusing on the project's potential for growth and interoperability. Discussions also highlight staking and upcoming partnerships.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as the community speculates on the impact of recent news and exchange listings. Community members are actively discussing price predictions and potential catalysts for growth, drawing comparisons to other meme coins. The listing and broader discussions around meme coins are driving interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OLMA Stock Soars 47% in September So Far on Second PFE Deal

Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.

Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent...

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 PR Newswire VANCOUVER...

Olema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at The Goldman Sachs Group

The Goldman Sachs Group began coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA - Free Report) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm issued a...

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( Olema or Olema Oncology , Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery...

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by Analysts

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA  Get Free Report) has earned an average recommendation of Buy from the seven brokerages that are currently covering the stock...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by EP Wealth Advisors LLC

EP Wealth Advisors LLC increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA  Free Report) by 831.1% in the third quarter, according to its most recent Form 13F filing...

Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 11.9%

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA  Get Free Report)s share price shot up 11.9% during mid-day trading on Wednesday . The company traded as high as $13.59 and last traded at...

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.47	--	--	N/A
Q2 '25	-$0.42	-$0.51	-20.50%	MISSED
Q1 '25	-$0.49	-$0.36	25.77%	BEAT
Q4 '24	-$0.63	-$0.51	19.07%	BEAT
Q3 '24	-$0.57	-$0.60	-5.07%	MISSED

OLMA
Olema Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest OLMA News

OLMAOlema Pharmaceuticals Inc